FDA’s GDUFA IV Adds Onshoring Incentives for Generics

FDA’s new GDUFA IV proposal keeps the 10-month review target and adds real incentives for domestic generic drug manufacturing.

The FDA’s proposed GDUFA IV commitment letter keeps the existing 10-month generic drug review target while adding new mechanisms specifically designed to encourage domestic manufacturing — a direct response to years of supply chain risk concerns.

What’s In the Proposal

The proposed enhancements aim to stabilize fee revenue, reduce the number of review cycles needed for generic drug approval, and improve program efficiency around complex data issues. Critically, the letter also introduces four new meeting types between FDA and applicants, alongside mechanisms specifically intended to facilitate onshoring of generic drug manufacturing.

The Fee Fight

The onshoring push aligns with Executive Order 14293, which targets expanded domestic manufacturing of essential medicines. FDA has noted that foreign facility fees have remained unchanged since GDUFA’s inception in FY 2013 — and the agency is now proposing to close that gap. Industry pushback has been immediate: generic manufacturers argue that raising foreign fees could push companies to exit the US generic drug market entirely rather than reshoring production.

What This Means for Procurement Teams

Track the foreign fee increase closely. If foreign facility fees rise substantially while domestic fees stay flat or are waived, the cost calculus for API and finished-dose sourcing decisions could shift meaningfully within the GDUFA IV cycle (FY 2028-2032).

New meeting types may accelerate your regulatory timeline. The four new meeting structures are designed to reduce review cycles — sponsors with complex generic applications should plan to use these touchpoints proactively rather than defaulting to standard correspondence.

This is not yet final. GDUFA IV requires congressional reauthorization before the current GDUFA III program expires at the end of September 2027 — treat these as strong directional signals for planning purposes, not locked policy.

FAQ

What is GDUFA IV?

It’s the fourth reauthorization of the Generic Drug User Fee Amendments, the FDA program funded by industry fees that supports the review and approval of generic drug applications, covering fiscal years 2028-2032.

What onshoring incentives does GDUFA IV propose?

The proposal includes mechanisms to facilitate domestic generic drug manufacturing, potential fee waivers for domestic facilities, and an increase to foreign facility fees, which have been unchanged since 2013.

Is GDUFA IV finalized?

No — it remains a proposed commitment letter requiring congressional reauthorization before GDUFA III expires at the end of September 2027.

Sources

• Endpoints News, GDUFA IV Commitments: New Onshoring Incentives and Meeting Types
• RAPS, GDUFA IV: Commitment Letter Outlines Key Changes to Program
• Federal Register, Reauthorization of the Generic Drug User Fee Amendments